A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
Trial details
- Registry ID
- NCT07502443
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as Alixorexton
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2NCT07502443 | Alkermes, Inc. | Phase 3 | Recruiting | 2027-05Estimated |
| A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1NCT07455383 | Alkermes, Inc. | Phase 3 | Recruiting | 2027-05Estimated |
| A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)NCT07540897 | Alkermes, Inc. | Phase 3 | Recruiting | 2027-06Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |